- Source: Olutasidenib
Olutasidenib, sold under the brand name Rezlidhia, is an anticancer medication used to treat relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation. Olutasidenib is an isocitrate dehydrogenase-1 (IDH1) inhibitor. It is taken by mouth.
The most common adverse reactions include nausea, fatigue/malaise, arthralgia, constipation, leukocytosis, dyspnea, fever, rash, mucositis, diarrhea, and transaminitis.
Olutasidenib was approved for medical use in the United States in December 2022, based on the phase 1 results of a phase 1/2 trial.
Medical uses
Olutasidenib is indicated for the treatment of adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Society and culture
= Names
=Olutasidenib is the international nonproprietary name.
References
Further reading
External links
"Olutasidenib". Drug Information Portal. U.S. National Library of Medicine.
Clinical trial number NCT02719574 for "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation" at ClinicalTrials.gov
Kata Kunci Pencarian:
- Olutasidenib
- Methotrexate
- Tretinoin
- Celecoxib
- Photodynamic therapy
- Nelarabine
- Hydroxycarbamide
- Acute myeloid leukemia
- Vorasidenib
- Carboplatin
